Pretreatment Considerations for Chronic Hepatitis C Virus Infection
This answer is incorrect. The patient's hepatitis C genotype remains the strongest viral factor and in some studies one of the strongest clinical factors, that determine the likelihood of treatment response. Patients with lower baseline HCV viral levels have tended to have slightly higher sustained virologic response rates with dual treatment with peginterferon and ribavirin, particularly if they have genotype 1 infection but this difference is attenuated with triple therapy that includes a HCV protease inhibitor. Investigators have identified multiple other factors, including IL28B status, race, degree of liver fibrosis, and coinfection with HIV, that may also predict treatment response.
Choose another answer: